Registration for a live webinar on 'Phasing Out Animal Testing: A New Era for Pharmaceutical Innovation' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and Risk Factors
-
1. Coronary heart disease epidemiology: global context for a new genetic understanding
- Prof. Harry Hemingway
-
2. Cardiovascular risk factors
- Dr. Michal Vrablik
-
3. Lipoproteins
- Prof. Arnold von Eckardstein
-
4. Thrombotic risk factors for cardiovascular disease
- Prof. Gordon Lowe
-
5. Lipoprotein(a)
- Dr. Jaimini Cegla
- Biology of Coronary Heart Disease
-
6. Plaque rupture
- Prof. Petri Kovanen
-
7. Transcription factors and complex disease development
- Dr. Ines Pineda-Torra
-
8. Animal models to explore cardiovascular disease
- Prof. Martin Merkel
- Treatment
-
9. Diagnosis and treatment of dyslipidemias
- Prof. Anton Stalenhoef
-
10. Key drug discovery challenges in cardiovascular medicine
- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Genetics
-
11. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
12. Heart disease genes and SNPs
- Prof. Steve Humphries
-
13. Familial hypercholesterolaemia: genetic causes and treatment
- Prof. Steve Humphries
-
14. Familial hypercholesterolaemia: cascade testing and monogenic vs. polygenic causes
- Prof. Steve Humphries
-
16. Genetics of cardiovascular disease
- Prof. Philippa Talmud
-
17. The genetics of CHD: moving research findings into patient benefit
- Prof. Steve Humphries
-
19. The genetics of abdominal aortic aneurysm
- Dr. Seamus Harrison
-
20. Genome scans for hypertension
- Prof. Patricia Munroe
-
21. Telomeres and cardiovascular disease
- Dr. Jess Buxton
-
23. Genetics of hypertrophic cardiomyopathy (HCM)
- Dr. Petros Syrris
- Archived Lectures *These may not cover the latest advances in the field
-
24. Gene-environment interaction and oxidative stress in cardiovascular disease
- Dr. Jeffrey Stephens
-
25. Gene therapy as a therapeutic option for lipoprotein lipase deficiency
- Dr. Jan Albert Kuivenhoven
-
26. Cardiovascular diseases: from epidemiology to nutritional interventions
- Dr. Antonis Zampelas
-
27. Genetic testing for CHD risk: fact or fiction?
- Prof. Steve Humphries
-
28. Pharmacogenetics: progress, pitfalls and clinical potential
- Prof. Steve Humphries
-
29. Familial hyperchlolesterolaemia: a monogenic cause of early CHD
- Prof. Steve Humphries
-
30. Lipid metabolism
- Dr. Ulrike Beisiegel
Printable Handouts
Navigable Slide Index
- Introduction
- Introduction (2)
- Problems with current risk factors
- Effects of risk factors on CVD mortality
- Prediction of CHD in diabetes
- Oxidative stress and cardiovascular risk
- Molecular consequences of oxidative stress
- The polygenic nature of CHD
- Gene environment interaction
- Genes load the gun, environment pulls the trigger
- Genetic & biochemical markers of oxidative stress
- Aim of this presentation
- Measurement of oxidative stress
- Plasma Total Antioxidant Status (TAOS)
- Mitochondrial uncoupling protein 2
- A novel antioxidant UCP2 ?
- Mitochondria are major source of cellular ROS
- UCL-diabetes and cardiovascular disease study
- Northwick park heart study II
- Prospective CHD risk by plasma TAOS in NPHSII
- UCP2 common variants
- Plasma TAOS and UCP2 -866G>A genotype
- Oxidative stress and UCP2 -866G>A genotype
- Plasma TAOS, smoking, and UCP2 -866G>A
- UCP2 genotype and CHD risk in NPHSII
- Other CHD risk factors
- The important of UCP2
- UCP2 environment interaction and CHD risk
- Does statin treatment reduce oxidative stress?
- Apolipoprotein E (APOE)
- APOE and CHD risk
- APOE genotype and CHD risk
- APOE and oxidative stress
- The APOE genotype interaction with smoking
- Glutathione s-transferase gene (GST)
- GSTs and oxidative stress
- The role of glutathione s-transferase
- GST gene variants
- GST gene variants and CVD
- Plasma Ox-LDL by GSTT1 genotype & smoking
- Other gene variants (1)
- Other gene variants (2)
- Summary overview
- Acknowledgments
Topics Covered
- Oxidative stress: a risk factor for CVD
- Biochemical markers of oxidative stress
- Genetic determinants of oxidative stress: examples
- Examples of gene-environment interaction in determining oxidative stress and CVD
- Other gene variants and oxidative stress
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stephens, J. (2008, November 24). Gene-environment interaction and oxidative stress in cardiovascular disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 21, 2025, from https://doi.org/10.69645/QYWF3240.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jeffrey Stephens has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Gene-environment interaction and oxidative stress in cardiovascular disease
A selection of talks on Cardiovascular & Metabolic
Hide